My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 701

    1.

    The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

    Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

    Ann Intern Med. 2003 May 20;138(10):795-806. Review.PMID: 12755551 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.

    Maetzel A, Krahn M, Naglie G.

    Arthritis Rheum. 2003 Jun 15;49(3):283-92.PMID: 12794781 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.

    [No authors listed]

    Ann Intern Med. 2003 May 20;138(10):I39. No abstract available. PMID: 12755582 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.

    Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA.

    Pharmacoeconomics. 2001;19(10):1039-49.PMID: 11735672 [PubMed - indexed for MEDLINE]Related articles

    5.

    Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration.

    Schaefer M, DeLattre M, Gao X, Stephens J, Botteman M, Morreale A.

    Curr Med Res Opin. 2005 Jan;21(1):47-60.PMID: 15881475 [PubMed - indexed for MEDLINE]Related articles

    6.

    Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.

    Spiegel BM, Chiou CF, Ofman JJ.

    Arthritis Rheum. 2005 Apr 15;53(2):185-97. Review.PMID: 15818647 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.

    Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.PMID: 18405470 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.

    Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, Rostom A, Symmons D.

    Health Technol Assess. 2006 Oct;10(38):iii-iv, xi-xiii, 1-183. Review.PMID: 17018227 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    An economic model of long-term use of celecoxib in patients with osteoarthritis.

    Loyd M, Rublee D, Jacobs P.

    BMC Gastroenterol. 2007 Jul 4;7:25.PMID: 17610716 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.

    Moore A, Phillips C, Hunsche E, Pellissier J, Crespi S.

    Pharmacoeconomics. 2004;22(10):643-60.PMID: 15244490 [PubMed - indexed for MEDLINE]Related articles

    11.

    What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

    Hochberg MC.

    Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.PMID: 11695246 [PubMed - indexed for MEDLINE]Related articles

    12.

    Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

    JAMA. 2000 Sep 13;284(10):1247-55.PMID: 10979111 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

    Hochberg MC.

    Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.PMID: 12528069 [PubMed - indexed for MEDLINE]Related articles

    14.

    Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.

    You JH, Lee KK, Chan TY, Lau WH, Chan FK.

    Aliment Pharmacol Ther. 2002 Dec;16(12):2089-96.PMID: 12452942 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.

    Becker RV, Burke TA, McCoy MA, Trotter JP.

    Clin Ther. 2003 Feb;25(2):647-62.PMID: 12749519 [PubMed - indexed for MEDLINE]Related articles

    16.

    The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.

    Harley C, Wagner S.

    Clin Ther. 2003 Jan;25(1):139-49.PMID: 12637116 [PubMed - indexed for MEDLINE]Related articles

    17.

    Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy.

    Fendrick AM.

    Cleve Clin J Med. 2002;69 Suppl 1:SI59-64. Review.PMID: 12086296 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group.

    N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528.PMID: 11087881 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.

    Hochberg MC.

    Curr Top Med Chem. 2005;5(5):443-8. Review.PMID: 15974939 [PubMed - indexed for MEDLINE]Related articles

    20.

    Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.

    Hochberg MC.

    Am J Manag Care. 2002 Nov;8(17 Suppl):S502-17. Review.PMID: 12458820 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity